GlassScriptPhysician profile
John T Gay
NPI 1912318544
$12,548.06
in general payments reported to CMS, 2019-2025
30 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $771 · 2021: $1,484 · 2022: $2,170 · 2023: $2,060 · 2024: $2,864 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,740 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,739.99 |
| Education | $197.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,686.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,401.93 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,338.55 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,131.02 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Ucb, INC. | $883.30 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $870.79 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $863.25 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $537.33 | 2019-2024 | |
| Amgen INC. | $463.80 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $442.02 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $414.40 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Genentech USA, INC. | $344.69 | 2019-2022 | |
| Incyte Corporation | $233.88 | 2021-2025 | Opzelura |
| Genzyme Corporation | $175.39 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $96.67 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $95.14 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $83.84 | 2023-2025 | Zoryve |
| Dusa Pharmaceuticals, INC. | $82.49 | 2019 | |
| Celgene Corporation | $76.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.63 | 2024-2025 | Spevigo |
| Alnylam Pharmaceuticals INC. | $47.00 | 2024 | Givlaari |
| Almirall LLC | $43.64 | 2025 | Seysara, Klisyri |
| Organon LLC | $43.33 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $42.83 | 2021-2025 | Nemluvio |
| Convatec INC. | $27.66 | 2024 | |
| Botanix Sb INC | $15.55 | 2025 | Sofdra |
| Leo Pharma INC. | $15.12 | 2019 | |
| Epi Health, LLC | $14.23 | 2022 | |
| Kyowa Kirin, INC. | $13.61 | 2025 | |
| Verrica Pharmaceuticals INC. | $13.11 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.